OBJECTIVES

This study evaluated the effectiveness of the hearWHO application in rapid screening of hearing loss among Philippine Air Force military personnel and verifies its results with Pure Tone Audiometry. It aimed to establish baseline data for future research on technological advancements in otolaryngology

The study employed a cross-sectional design and recruited 44 volunteer subjects from the Philippine Air Force using inclusion criteria. Six participants withdrew due to an urgent mission, leaving 38 subjects who were screened using the hearWHO application and subsequently tested with Pure Tone Audiometry. A statistician analyzed the collected data.

A one-sample t-test revealed negative mean differences between hearWHO and Pure Tone Audiometry results indicating that they were not significant. Confounders such as testing room location, use of adapters and non-purposive sampling may have affected the results.

The results suggested that the hearWHO application was not effective in rapid screening of hearing loss among the military personnel of the Philippine Air Force.

We describe the development of quinolylnitrones (QNs) as multifunctional ligands inhibiting cholinesterases (ChEs: acetylcholinesterase and butyrylcholinesterase-hBChE) and monoamine oxidases (hMAO-A/B) for the therapy of neurodegenerative diseases. We identified QN 19, a simple, low molecular weight nitrone, that is readily synthesized from commercially available 8-hydroxyquinoline-2-carbaldehyde. Quinolylnitrone 19 has no typical pharmacophoric element to suggest ChE or MAO inhibition, yet unexpectedly showed potent inhibition of hBChE (IC₅₀ = 1.06 ± 0.31 nmol/L) and hMAO-B (IC₅₀ = 4.46 ± 0.18 μmol/L). The crystal structures of 19 with hBChE and hMAO-B provided the structural basis for potent binding, which was further studied by enzyme kinetics. Compound 19 acted as a free radical scavenger and biometal chelator, crossed the blood-brain barrier, was not cytotoxic, and showed neuroprotective properties in a 6-hydroxydopamine cell model of Parkinson's disease. In addition, in vivo studies showed the anti-amnesic effect of 19 in the scopolamine-induced mouse model of AD without adverse effects on motoric function and coordination. Importantly, chronic treatment of double transgenic APPswe-PS1δE9 mice with 19 reduced amyloid plaque load in the hippocampus and cortex of female mice, underscoring the disease-modifying effect of QN 19.